Clinical Trials Logo

Clinical Trial Summary

A physical training program will improve quality of life, participation in physical activity, motor coordination, muscle strength, and bone and muscle strength in children with neurofibromatosis type 1.


Clinical Trial Description

Disorders of the Ras pathway have significant phenotypic overlap and include Noonan syndrome, Cardiofaciocutaneous syndrome (CFC syndrome), Legius syndrome, Costello syndrome and neurofibromatosis type 1 (NF1). NF1 is one of the most common genetic disorders presenting in childhood with an incidence of 1/3000. NF1 is associated with skeletal abnormalities such as short stature, scoliosis, and long bone fracture with non-union. We recently reported that children with NF1 have abnormalities of bone and muscle architecture as evidenced by decreased bone mineral density, decreased bone strength, and low muscle mass, all of which may predispose them to fractures and scoliosis (Stevenson et al., 2005, 2007, 2009). Our preliminary data show that children with NF1 have poor motor coordination and muscle strength, potentially secondary to abnormal neuromotor learning. We hypothesize that poor motor coordination and decreased muscle strength contribute to the osteopenia in NF1. Our objective is to identify effective and non-invasive strategies to improve motor coordination, muscle strength, and bone and muscle architecture in children with disorders of the Ras pathway, in hopes of decreasing fractures and improving physical activity levels. Plyometric physical training consists of quick, high-intensity, weight-bearing movements, and is an encouraging intervention for use in these children. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01058330
Study type Interventional
Source Shriners Hospitals for Children
Contact
Status Completed
Phase N/A
Start date February 2010
Completion date February 2014

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03190915 - Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Phase 2
Completed NCT03326388 - Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Phase 1/Phase 2
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Active, not recruiting NCT01362803 - AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Phase 1/Phase 2
Active, not recruiting NCT01218139 - Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients N/A
Recruiting NCT05149469 - Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
Not yet recruiting NCT02505412 - Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients N/A
Terminated NCT02256124 - Effect of Lamotrigine on Cognition in NF1 Phase 2/Phase 3
Completed NCT01707836 - Neurofibromatosis Type 1 Brain Tumor Genetic Risk N/A
Active, not recruiting NCT01218152 - Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs N/A
Recruiting NCT03975829 - Pediatric Long-Term Follow-up and Rollover Study Phase 4
Recruiting NCT05186870 - Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
Active, not recruiting NCT03231306 - Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Phase 2
Withdrawn NCT03332030 - Stem Cells in NF1 Patients With Tumors of the Central Nervous System
Recruiting NCT02964884 - Interventions for Reading Disabilities in NF1 Phase 2
Recruiting NCT05388370 - PASS of Paediatric Patients Initiating Selumetinib
Recruiting NCT02777775 - Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Completed NCT02944032 - Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 N/A
Completed NCT01851135 - Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 N/A
Completed NCT01410006 - Neurofibromatosis Type 1 Patient Registry N/A